Hematopoietic stem cell transplantation in the treatment of lymphoma: reports from the 56th American Society of Hematology annual meeting / 白血病·淋巴瘤
Journal of Leukemia & Lymphoma
; (12): 13-16, 2015.
Article
em Zh
| WPRIM
| ID: wpr-474731
Biblioteca responsável:
WPRO
ABSTRACT
The 56th American Society of Hematology (ASH) annual meeting has reported 171 abstracts about hematopoietic stem cell transplantation (HSCT) for treating lymphoma,including 102 autologous HSCT (auto-HSCT) and 69 allogeneic HSCT (allo-HSCT),which mainly covered clinical effects of HSCT on patients with relapse/refractory Hodgkin lymphoma and high risk,aggressive non-Hodgkin lymphoma,as well as the impact factors such as the best time for transplantation,improvement of conditioning regimen,applying target chemotherapy prior to transplantation,preventing graft-versus-host disease (GVHD),and predictors for transplantation outcome.
Texto completo:
1
Base de dados:
WPRIM
Tipo de estudo:
Prognostic_studies
Idioma:
Zh
Revista:
Journal of Leukemia & Lymphoma
Ano de publicação:
2015
Tipo de documento:
Article